Charles River bags antibody discovery-focused Distribution Bio for $104M, signaling return to pre-pandemic buyout spree

Charles River Labs, one of the biggest CROs that specializes in preclinical research programs, has inked a new discovery pact as part of a string of deals over the last few years. And after the Covid-19 pandemic proved less of a financial burden than expected, the company could be ready to make even more moves.